922170-67-0

Basic information

• Product Name: 4-BroMo-2-Methyl-6-iodoaniline
• Synonyms: 4-BroMo-2-Methyl-6-iodoaniline;4-Bromo-2-iodo-6-methylaniline;4-bromo-2-iodo-6-methylbenzenamine
• CAS NO: 922170-67-0
• Molecular Formula: C₇H₇BrIN
• Molecular Weight: 311.94565
• EINECS: -0
• Mol File: 922170-67-0.mol

Chemical Properties

• Boiling Point: 302.8±42.0 °C(Predicted)
• Appearance: /
• Density: 2.133±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 1.69±0.10(Predicted)
• CAS DataBase Reference: 4-BroMo-2-Methyl-6-iodoaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BroMo-2-Methyl-6-iodoaniline(922170-67-0)
• EPA Substance Registry System: 4-BroMo-2-Methyl-6-iodoaniline(922170-67-0)

Safety Data

• Hazardous Substances Data: 922170-67-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-2-methyl-6-iodoaniline is used as a building block in organic synthesis for the production of pharmaceuticals. Its unique chemical structure allows it to be a key component in the development of various medications, contributing to the advancement of healthcare and treatment options.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Bromo-2-methyl-6-iodoaniline is utilized as a precursor in the synthesis of agrochemicals. Its properties make it suitable for creating compounds that can be used in pest control, crop protection, and other agricultural applications, thereby supporting food production and security.
Used in Fine Chemicals Industry:
4-Bromo-2-methyl-6-iodoaniline is also employed in the production of other fine chemicals. Its versatility as a chemical intermediate enables its use in a wide range of applications, from specialty chemicals to advanced materials, further expanding its utility across various industries.

Upstream product

• 583-75-5 4-Bromo-2-methylaniline 

Downstream Products

• 1092585-75-5 tert-butyl 4-bromo-2-iodo-6-methylphenylcarbamate 
• 1354311-05-9 C₁₆H₁₃BrINO 
• 1093966-37-0 2-amino-5-bromo-3-methylbenzonitrile 

Relevant articles and documents

Preparation method of 5-bromo-7-methylindole

The invention discloses a preparation method of 5-bromo-7-methylindole. The structure of an intermediate corresponds to a formula V. The preparation method comprises the following steps: using 4-bromo-2-methylaniline as an initial raw material, and carryi

Discovery of a series of 1H-pyrrolo[2,3-b]pyridine compounds as potent TNIK inhibitors

In an in-house screening, 1H-pyrrolo[2,3-b]pyridine scaffold was found to have high inhibition on TNIK. Several series of compounds were designed and synthesized, among which some compounds had potent TNIK inhibition with IC50 values lower than 1 nM. Some compounds showed concentration-dependent characteristics of IL-2 inhibition. These results provided new applications of TNIK inhibitors and new prospects of TNIK as a drug target.

Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay

Inappropriate activation of endosomal TLR7 and TLR8 occurs in several autoimmune diseases, in particular systemic lupus erythematosus (SLE). Herein, the development of a TLR8 antagonist competition assay and its application for hit generation of dual TLR7

Isothiourea-Catalyzed Atroposelective N-Acylation of Sulfonamides

We report herein an atroposelective N-acylation of sulfonamides using a commercially available isothiourea catalyst, (S)-HBTM, with a simple procedure. The N-sulfonyl anilide products can be obtained in good to high enantiopurity, which represents a new axially chiral scaffold. The application of the product as a chiral iodine catalyst is also demonstrated for the asymmetric α-oxytosylation of propiophenone.

ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES

The present invention relates to pyrazole fused-ring derivatives, their preparation methods, and use thereof in medicine. In particular, the present invention relates to a novel derivative represented by formula (I), and a pharmaceutically acceptable salt

Synthesis of shape-persistent macrocycles with three 1,8-diazaanthracene units and their packing in the single crystal

The synthesis of four shape-persistent macrocycles with three 1,8-diazaanthracene units each is reported (2,3 a-3 c). For two of them single crystals could be obtained and the structures in the crystal be solved. The structures reveal that macrocycle 2 se

INHIBITORS OF IKK-BETA SERINE-THERONINE PROTEIN KINASE

Cyclopentyl(2S,4E)-2-amino-5-{3-[4-carbamoyl-5(carbamoylamino)-2-thienyl]phenyl}pent-4-enoate; Cyclopentyl 5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-norvalinate; Cyclopentyl(2S,4E)-2-amino-5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-5-m

2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization

We describe structure-based optimization of a series of novel 2,4-diaminopyrimidine MK2 inhibitors. Co-crystal structures (see accompanying Letter) demonstrated a unique inhibitor binding mode. Resulting inhibitors had IC50 values as low as 19 nM and moderate selectivity against a kinase panel. Compounds 15, 31a, and 31b inhibit TNFα production in peripheral human monocytes.

INHIBITORS OF IKK-β SERINE-THREONINE PROTEIN KINASE

Cyclopentyl (2S,4E)-2-amino-5-{3-[4-carbamoyl-5 (carbamoylamino)-2-thienyl]phenyl}pent-4-enoate; Cyclopentyl 5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-norvalinate; Cyclopentyl (2S,4E)-2-amino-5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-